Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Mid-Morning Market Update: Markets Edge Lower; Pfizer Profit Misses Views

Benzinga.com  November 1, 2016

The Market In 5 Minutes: Pfizer's Earnings, Gannett Drops Tronc Bid

Benzinga.com  November 1, 2016

A Peek Into The Markets: U.S. Stock Futures Rise Following Strong Chinese Manufacturing Report

Benzinga.com  November 1, 2016

PFIZER REPORTS THIRD-QUARTER 2016 RESULTS

Business Wire November 1, 2016

Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor

Business Wire November 1, 2016

Watch These 7 Huge Call Purchases In Tuesday Trade

Benzinga.com  November 1, 2016

October 2016 Sets Record For M&A At $251 Billion

Benzinga.com  October 31, 2016

Learn how to target a 17% return on Cardinal Health, or get option-trade ideas on Capital One, Dean Foods, Pfizer Inc. and Regeneron Pharmaceuticals or any stock you choose

PR Newswire October 31, 2016

European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

PR Newswire October 31, 2016

Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson

PR Newswire October 26, 2016

6 Big Pharma Companies Left To Report September Quarterly Figures

Benzinga.com  October 25, 2016

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

PR Newswire October 21, 2016

Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy

Canada NewsWire October 20, 2016

CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)

Business Wire October 19, 2016

Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation

Benzinga.com  October 19, 2016

Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection

Business Wire October 19, 2016

Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)

Business Wire October 17, 2016

Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016

Business Wire October 15, 2016

The Market In 5 Minutes: Stumpf Leaves Wells Fargo, More Trump Allegations

Benzinga.com  October 13, 2016

Theravance Biopharma's Valuation Has Gotten A Little Carried Away

Benzinga.com  October 12, 2016